|
Brainstorm Cell Therapeutics Inc (BCLI) CEO Chaim Lebovits on Q2 2020 Results - Earnings Call Transcript
seekingalpha.com/article/...-on-q2-2020-results-earnings-call
We have never been in such a strong financial position. We have no debt, no convertibles or the like, we today are close to $35 million cash on hand. I will begin this morning’s call with some introductory remarks and general corporate updates at BrainStorm.
...
Thank you Chaim and thank you everyone for joining us today on the earnings call. Let me start with an update on our Phase III pivotal trial of neuron in ALS. As a reminder, the trial is being conducted at six ALS of excellence in the U.S., it has enrolled approximately 200 participants, randomized one-to-one to receive three doses of neuron or placebo. These were administered over four months and then participants in the trial are followed for a total of 28 weeks.
...
At BrainStorm, we are staffing up a highly experienced team. And we are very busy on a day-to-day basis planning and executing to support data readouts on all pre-BLA activities. Our clear focus is to expedite this process. We want to be able to submit a Biologic License Application or BLA with the FDA as soon as possible after the top line data is available.
...
I’m also happy to report that our progressive MS trial is now fully enrolled. Despite facing severe COVID-19 hospital restrictions in the spring, we still expect all study treatments to be completed by the end of this year.
Brainstorm Announces Grant of a New Japanese Patent for NurOwn®
https://www.ariva.de/news/...ant-of-a-new-japanese-patent-for-8739519
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japanese Patent Office (JPO) has granted Brainstorm's Japanese Patent, number: 6,753,887, titled: 'Methods of Generating Mesenchymal Stem Cells which Secrete Neurotrophic Factors'.
...
David Setboun, PharmD MBA, EVP and Chief Operating Officer, added: "Having our cell therapy product patented in Japan will increase our ability to enter into new commercial partnerships for NurOwn® in Japan."
BrainStorm Announces Scientific Presentation at the Annual NEALS Meeting
https://www.ariva.de/news/...tific-presentation-at-the-annual-8775779
announced the presentation of a poster titled, "Advancing NurOwn® for ALS: Phase 3 Clinical Trial Design" at the Annual Northeast ALS (NEALS) Meeting, being held virtually.
...
Compelling Phase 2 data showed that a single NurOwn® administration slowed disease progression in this patient population, and the current Phase 3 trial aims to confirm this effect in a larger study cohort and show that its duration can be extended through repeated administrations.
...
BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa
https://www.ariva.de/news/...he-2020-cell-amp-gene-meeting-on-8806252
Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2020 Cell & Gene Meeting on the Mesa, being held virtually October 12-16, 2020.
...
a copy of the presentation will also be available in the "Investors and Media" section of the BrainStorm website under Events and Presentations.
Topline Results from NurOwn® Phase 3 ALS Study
"Clinical trial did not meet statistical significance in primary efficacy endpoint"
ir.brainstorm-cell.com/...lts-from-NurOwn-R-Phase-3-ALS-Study
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
51 | BrainStorm Cell Therapeutics! | iwanooze | Vassago | 18.10.23 12:18 |